

**VEDOLIZUMAB solution for infusion (Entyvio®)
for chronic refractory pouchitis after surgery for ulcerative colitis**

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of VEDOLIZUMAB solution for infusion (Entyvio®) for chronic refractory pouchitis after surgery for ulcerative colitis.

GREY

Vedolizumab has been granted a license extension and is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of chronic refractory pouchitis should continue to follow local pathways and local formulary choices.

References

1. Takeda UK Ltd. Summary of Product Characteristics; [Entyvio 300 mg powder for concentrate for solution for infusion](#), 11 March 2022. Accessed 17 May 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.